Sandi Block

Sandi Block has a diverse work experience spanning over a decade. Sandi currently holds the position of Associate Director, Clinical Operations at RayzeBio since May 2023. Prior to that, they worked as a Sr. Clinical Trial Manager (Consultant) at Denali Therapeutics from February 2022 to April 2023.

Sandi had a significant tenure at Bristol Myers Squibb, where they started as a Sr. Global Trial Manager in November 2020 and continued until December 2021. During their time at Bristol Myers Squibb, they played a key role in the acquisition of MyoKardia. Sandi was also the Study Lead of Open Label Extension and played a crucial role in the approval of Mavacamten by the FDA in April 2022.

Before their stint at Bristol Myers Squibb, Sandi worked at MyoKardia as a Clinical Trial Lead from September 2020 to November 2020 and as a Clinical Trial Manager (Consultant) from January 2019 to August 2020.

Sandi gained valuable experience at Portola Pharmaceuticals, where they worked as a Clinical Trial Manager from January 2018 to December 2018. Sandi also held the positions of Sr. Clinical Research Associate (In-house) from January 2017 to January 2018 and Clinical Research Associate (In-house) from May 2015 to January 2017 at the same company. While at Portola Pharmaceuticals, they made significant contributions to the FDA and EMA approval of Andexanet and played a leading role in various global phase III/IV and phase I studies.

Sandi started their professional journey at Genoptix Medical Laboratory, a Novartis Company, where they held multiple roles, including BioPharma Project Coordinator from November 2013 to April 2015, Clinical Trial Associate Intern from September 2013 to November 2013, and Clinical Study Assistant Intern from June 2013 to November 2013.

Prior to that, they worked as a Department Coordinator (CCE Program) at COPE Health Solutions from August 2012 to March 2013 and as a Clinical Care Extender (CCE) at St. Francis Medical Center from March 2012 to March 2013.

Sandi started their career as a Research Assistant Intern in the Program of Apoptosis and Cell Death Research at Sanford-Burnham Medical Research Institute in June 2011 and worked until August 2011. Sandi also gained experience as a Patient Relations Intern at Accuray from January 2010 to May 2010.

Overall, Sandi's extensive work experience showcases their expertise in clinical operations, trial management, and regulatory approvals. Sandi'scontributions to various studies and acquisitions demonstrate their ability to drive successful outcomes in the pharmaceutical industry.

Sandi Block attended Santa Clara University from 2008 to 2010, where they pursued a Bachelor of Arts (B.A.) degree in Biology/Biological Sciences, General. Following that, they transferred to the University of Southern California and completed their Bachelor of Arts (B.A.) degree in Biology/Biological Sciences, General from 2010 to 2013.